Luteolin and luteolin-7-<i>O</i>-glucoside protect against acute liver injury through regulation of inflammatory mediators and antioxidative enzymes in GalN/LPS-induced hepatitic ICR mice

Park, Chung Mu; Song, Young‐Sun

doi:10.4162/nrp.2019.13.6.473

Cited by 43 publications

(22 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anti-inflammatory and antioxidant activities induced by luteolin were investigated in an in vivo model of galactosamine/lipopolysaccharide-induced hepatotoxicity. As expected, luteolin provided a protecting effect against acute liver injury by regulating inflammatory mediators and phase II enzymes [ 103 ]. However, the use of luteolin was as a liver-protecting agent as ancient origins, since this flavonoid is abundant in Achillea millefolium , a plant traditionally being used to treat liver diseases in India.…”

Section: Preclinical Pharmacological Activities Of Luteolin: In Vivo Evidencesupporting

confidence: 61%

Paving Luteolin Therapeutic Potentialities and Agro-Food-Pharma Applications: Emphasis on In Vivo Pharmacological Effects and Bioavailability Traits

Taheri

Sharifi‐Rad

Antika

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Luteolin is a naturally occurring secondary metabolite belonging to the class of flavones. As many other natural flavonoids, it is often found in combination with glycosides in many fruits, vegetables, and plants, contributing to their biological and pharmacological value. Many preclinical studies report that luteolin present excellent antioxidant, anticancer, antimicrobial, neuroprotective, cardioprotective, antiviral, and anti-inflammatory effects, and as a consequence, various clinical trials have been designed to investigate the therapeutic potential of luteolin in humans. However, luteolin has a very limited bioavailability, which consequently affects its biological properties and efficacy. Several drug delivery strategies have been developed to raise its bioavailability, with nanoformulations and lipid carriers, such as liposomes, being the most intensively explored. Pharmacological potential of luteolin in various disorders has also been underlined, but to some of them, the exact mechanism is still poorly understood. Given the great potential of this natural antioxidant in health, this review is aimed at providing an extensive overview on the in vivo pharmacological action of luteolin and at stressing the main features related to its bioavailability, absorption, and metabolism, while essential steps determine its absolute health benefits and safety profiles. In addition, despite the scarcity of studies on luteolin bioavailability, the different drug delivery formulations developed to increase its bioavailability are also listed here.

show abstract

Section: Preclinical Pharmacological Activities Of Luteolin: In Vivo Evidencesupporting

confidence: 61%

Paving Luteolin Therapeutic Potentialities and Agro-Food-Pharma Applications: Emphasis on In Vivo Pharmacological Effects and Bioavailability Traits

Taheri

Sharifi‐Rad

Antika

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…Lu could inhibit the production and release of inflammatory factors in serum and liver of mice with liver injury induced by D-GaI/LPS. Park et al found that luteolin administration significantly ameliorated the increased TNF- α production and COX-2 expression in GalN/LPS-induced hepatitic ICR mice [ 18 ]. Attiq et al reported Lu abrogates the LPS-induced inflammatory responses in human plasma, especially decreased the expression of IL-1 β and IL-6 [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Protective Effect of Luteolin on D-Galactosamine (D-Gal)/Lipopolysaccharide (LPS) Induced Hepatic Injury by in Mice

Yang

2021

BioMed Research International

View full text Add to dashboard Cite

To observe the effects of luteolin on galactosamine (D-Gal)/lipopolysaccharide (LPS) induced liver injury in mice. Male C57BL/6 mice were randomly divided into 4 groups: normal control group, D-GaI/LPS group, D-GaI/LPS + luteolin (Lu, 20 mg/kg), and D-GaI/LPS + luteolin (Lu, 40 mg/kg). Mice in the normal control group and D-GaI/LPS group were given distilled water while other groups were given drugs in 7 days by gavage. 4 hours after the continuous administration, Gal (700 mg/kg) and LPS (10 mg/kg) were injected intraperitoneally. Mice in the normal control group were given the same volume of vegetable oil solution. 24 h after the establishment of the mice model, blood and liver samples were collected. Hematoxylin (HE) staining was used to observe the changes of hepatic histopathology. Alanine aminotransferase (ALT) and glutamic oxalacetic transaminase (AST) in serum, interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor (TNF-α) were measured by related kits. Western blotting was used to demonstrate the expression levels of related inflammation proteins. Lu significantly reduced levels of proinflammatory cytokines including interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) in serum and liver. Lu restored the pathological changes after galactosamine (D-Gal)/lipopolysaccharide (LPS) treatment. In addition, Lu regulated proteins levels of the NLRP3/NF-κB pathway in liver. Lu exhibited therapeutical effects on D-GaI/LPS induced liver injury in mice which might be related to the regulation of the NLRP3/NF-κB pathway.

show abstract

“…Luteolin is a flavone compound present as glycosides in many vegetables and fruits, including celery, pepper, thyme, and broccoli (Lopez-Lazaro, 2009 ). It possesses a broad range of pharmacological properties such as anticancer, neuroprotective, antioxidant, and immunomodulatory capacities ( Imran et al, 2019 ; Park & Song, 2019 ; Xagorari et al, 2001 ). The current advancements of in silico , in vitro , and in vivo studies reveal that luteolin exhibit strong anti-inflammatory activities via regulation of MAPK in the AP-1 (activator protein −1) pathway, Src in the NF-κB pathway, and SOCS3 in the STAT3 (signal transducer and activator of transcription 3) pathway (Aziz et al, 2018 ).…”

Section: Anti-inflammatory Compounds Against Multiple Therapeutic Targets Of Sars-cov-2mentioning

confidence: 99%

Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications

Naik

Mattaparthi

Gupta

et al. 2021

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

In view of many European countries and the USA leading to the second wave of COVID-19 pandemic, winter season, the evolution of new mutations in the spike protein, and no registered drugs and vaccines for COVID-19 treatment, the discovery of effective and novel therapeutic agents is urgently required. The degrees and frequencies of COVID-19 clinical complications are related to uncontrolled immune responses, secondary bacterial infections, diabetes, cardiovascular disease, hypertension, and chronic pulmonary diseases. It is essential to recognize that the drug repurposing strategy so far remains the only means to manage the disease burden of COVID-19. Despite some success of using single-target drugs in treating the disease, it is beyond suspicion that the virus will acquire drug resistance by acquiring mutations in the drug target. The possible synergistic inhibition of drug efficacy due to drug-drug interaction cannot be avoided while treating COVID-19 and allied clinical complications. Hence, to avoid the unintended development drug resistance and loss of efficacy due to drug-drug interaction, multi-target drugs can be promising tools for the most challenging disease. In the present work, we have carried out molecular docking studies of compounds from the FDA approved drug library, and the FDA approved and passed phase −1 drug libraries with ten therapeutic targets of COVID-19. Results showed that known drugs, including nine anti-inflammatory compounds, four antibiotics, six antidiabetic compounds, and one cardioprotective compound, could effectively inhibit multiple therapeutic targets of COVID-19. Further in-vitro , in vivo , and clinical studies will guide these drugs' proper allocation to treat COVID-19. Communicated by Ramaswamy H. Sarma

show abstract

Luteolin and luteolin-7-O-glucoside protect against acute liver injury through regulation of inflammatory mediators and antioxidative enzymes in GalN/LPS-induced hepatitic ICR mice

Cited by 43 publications

References 37 publications

Paving Luteolin Therapeutic Potentialities and Agro-Food-Pharma Applications: Emphasis on In Vivo Pharmacological Effects and Bioavailability Traits

Paving Luteolin Therapeutic Potentialities and Agro-Food-Pharma Applications: Emphasis on In Vivo Pharmacological Effects and Bioavailability Traits

Protective Effect of Luteolin on D-Galactosamine (D-Gal)/Lipopolysaccharide (LPS) Induced Hepatic Injury by in Mice

Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications

Contact Info

Product

Resources

About